Checkpoint kinase 1 is critical for S-phase fidelity and preventing premature mitotic entry in the presence of DNA damage. Tumour cells have developed a strong dependence on CHK1 for survival and hence this kinase has developed into a popular drug-target. Chk1-deficiency in mice results in blastocyst death due to G2/M checkpoint-failure showing that it is an essential gene and may be difficult to target therapeutically without side-effects. Here, we show that chemical inhibition of CHK1 kills murine hematopoietic stem and progenitor cells (HSPCs) as well as human CD34 + HSPCs by the induction of BCL2-regulated but p53-independent apoptosis. Moreover, Chk1 is essential for stem cell survival and definite hematopoiesis in the mouse embryo. Remarkably though, cell death inhibition in hematopoietic stem cells (HSC)
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Checkpoint kinase 1 is critical for S-phase fidelity and preventing premature mitotic entry in the presence of DNA damage. Tumour cells have developed a strong dependence on CHK1 for survival and hence this kinase has developed into a popular drug-target. Chk1-deficiency in mice results in blastocyst death due to G2/M checkpoint-failure showing that it is an essential gene and may be difficult to target therapeutically without side-effects. Here, we show that chemical inhibition of CHK1 kills murine hematopoietic stem and progenitor cells (HSPCs) as well as human CD34 + HSPCs by the induction of BCL2-regulated but p53-independent apoptosis. Moreover, Chk1 is essential for stem cell survival and definite hematopoiesis in the mouse embryo. Remarkably though, cell death inhibition in hematopoietic stem cells (HSC)
cannot restore blood cell formation in utero as Chk1 loss causes severe DNA damage that ultimately prevents HSC expansion. Our findings establish a previously unrecognized role for CHK1 in establishing hematopoiesis; they also suggest adverse effects of therapeutic CHK1-inhibtion, particularly under conditions forcing stem cells out of dormancy, such as chemotherapy-induced myelosuppression.
INTRODUCTION
The hematopoietic system originates from one specialized cell type, the hematopoietic stem cell (HSC). Remarkably, HSCs are not the first blood cells that can be detected in mammals.
Indeed, at around embryonic day 7.5 (E7.5) in mice the first blood cells can be detected in socalled blood-islands, which are found in extra-embryonic tissue like the placenta, the vitelline duct and the yolk sac (1-4). These blood cells, primitive erythrocytes and macrophages, arise from primitive HSC (pHSC) that have limited properties in colony formation assays and are unable to reconstitute the adult blood system in bone-marrow transplantation experiments (5, 6) . In contrast, definite HSC (dHSC) are capable of establishing the entirety of all blood cells of an organism and have self-renewal capacity for life. Both, pHSC and dHSC develop from a common ancestor, an Etv2 + Flk1 + mesodermal cell with endothelial and hematopoietic potential (6) (7) (8) . RUNX1 and GATA transcription factors dictate their fate. GATA1 + RUNX1 + cells define pHSC that provide the embryo with primitive erythrocytes and macrophages until birth when blood formation starts to rely entirely on dHSC (9) . Cells that down-regulate RUNX1
commit as "angioblasts" to the endothelial lineage. Together with GATA1 -RUNX1 + cells, angioblasts contribute to the formation of the hemogenic endothelium at E8.0. Lineage tracing experiments have shown that GATA1 -RUNX1 + cells commit to the hematopoietic lineage and are therefore the first dHSC detectable in the dorsal aorta of the aorta-gonad-mesonephros (AGM) at E9.5-10.5 (10) . From there, dHSC migrate to, expand and initiate the first wave of definite hematopoiesis in the fetal liver between E11.5-E14.5 (11) and are dependent on GATA2 for survival (12) . Shortly before birth, dHSC migrate further to the bone marrow to reside there in specific niches protected from environmental threats but responsive to cues that define the need to replenish the hematopoietic system (13, 14) .
Long-term HSC (LT-HSC) in the adult have self-renewal capacity but reside in a quiescent state for most of their lifetime (15) . LT-HSCs divide asymmetrically into one daughter with short-term (ST) reconstitution potential, differentiating into a multi-potent progenitor (MPP) cell and the other one remaining a bona fide stem cell (16) . MPPs then commit to the myeloid, lymphoid or erythroid/megakaryocyte lineage. These transient amplifying progenitors with limited lineage potential provide the organism with the blood cells needed. To fulfil this task, the cell cycle of LT-HSCs and their immediate progeny is tightly regulated intrinsically but also responds to signals from the bone marrow micro-environment. Macrophages, for example, are thought to influence Nestin + mesenchymal stem cells (MSCs) to stop secreting stem cell factor (SCF), angiopoietin-1, CXCL12 and vascular cell adhesion molecule (VCAM) 1, to induce cell cycle entry in HSCs (17) . Furthermore, regulatory T-cells, Schwann cells and osteoblasts were reported to locally inhibit HSC expansion (18) (19) (20) . Intrinsically, HSC-quiescence is promoted by the polycomb-protein BMI1 and the p53 tumor suppressor (15, 21) .
The serine/threonine kinase checkpoint kinase 1 (CHK1) is a critical cell cycle regulator that controls normal proliferation and is activated in response to DNA-damage, thereby also controlling p53 function (22, 23) . Especially upon single-stranded DNA breaks, ataxiatelangiectasia and Rad3-related protein (ATR) phosphorylates CHK1, leading to its activation and stabilisation (24) . On the one hand, active CHK1 arrests the cell cycle via inhibition of CDC25 phosphatases that are essential for the activity of Cyclin/CDK-complexes. CHK1 phosphorylated CDC25A is marked for ubiquitination and therefore protesomal degradation leading to a drop in CDK2-activity and subsequent G1/S-arrest (25, 26) . On the other hand, CDC25C is retained in the cytoplasm by 14-3-3 proteins when phosphorylated by CHK1 upon DNA damage, restraining CDK1-activity leading to a G2/M-arrest (27) . Moreover, CHK1
promotes the activity of MYT1 and WEE1 kinases that both inhibit CDK1 by phosphorylation blocking transition from G2 to M-phase (28, 29) . Under these conditions, CHK1 can stabilize p53 by direct phosphorylation to tighten cell cycle arrest (30, 31) . In the absence of p53, however, cells become highly dependent on CHK1 for cell cycle control, arrest and repair of DNA damage (24, 26) , generating a vulnerability that is currently explored as a means to treat cancers with CHK1 inhibitors (23, 32) .
Chk1 deletion in mice was shown to be embryonic lethal around E5.5 due to G2/M checkpoint failure. Blastocysts lacking Chk1 exhibit massive DNA damage and cell death that could not be overcome by co-deletion of p53 (33, 34 (40) (41) (42) , as well as during natural aging (43, 44 ), it appears appropriate that HSCs arm themselves with CHK1 to immediately deal with the dangers of a sudden proliferative challenge to avoid mutational spread. Yet, another study found that Chk1 mRNA levels are low in HSC but increase during proliferation-coupled selfrenewal or differentiation, along with other DNA damage response and repair genes (43) .
Consistent with a direct link to proliferation, Chk1 mRNA was also found to be higher in fetal liver vs. bone-marrow derived HSC from young or aged mice (43) . Notably here, HSC from old mice suffer from enhanced replication stress upon mobilization that triggers substantial CHK1 activation (44) . Together this suggests critical roles for CHK1 in stem cell dynamics and prompted us to elucidate its role in the development and survival of the hematopoietic stem and progenitor cells. Using a conditional allele for Chk1 in combination with a CRE-deleter strain allowing recombination of this allele within the hematopoietic system, we were able to highlight the importance of Chk1 for the establishment of hematopoiesis in the embryo and the survival of HSPCs from mice and man.
RESULTS

CHK1 inhibition limits the survival of hematopoietic progenitors by inducing mitochondrial apoptosis
To explore the consequences of CHK1 inhibition on pluripotent hematopoietic precursors we first assessed the response of Hoxb8-immortalized FLT3-dependent progenitor cells (Hoxb8-FL cells). These cells can be generated from murine bone marrow and are multi-potent progenitor (MPP)-like cells that can be differentiated in vitro into myeloid and lymphoid lineages (45) . Treatment of Hoxb8-FL cells with two specific CHK1 inhibitors (CHK1i), PF-477736 (PF)
or CHIR-124 (CHIR) resulted in time and dose-dependent cell death, as assessed by propidium iodide (PI) staining of DNA-content by flow cytometric analysis ( Figure 1A , Figure   S1 ). Hoxb8-FL cells generated from Vav-BCL2-transgenic mice or mice lacking the keyapoptotic effectors Bax and Bak were protected from cell death indicating initiation of caspasedependent mitochondrial apoptosis after CHK1i treatment ( Figure 1A ). The rapid cell death seen in wild type cells was accompanied by gH2AX accumulation, p53-stabilization, and PARP1 cleavage, as detected in western analyses ( Figure 1B ). As gH2AX phosphorylation is also induced during apoptosis due to CAD-mediated cleavage of DNA between nucleosomes (46), we wondered if this may be a secondary consequence of caspase-activation.
Consistently, upon CHK1 inhibition, Hoxb8-FL cells lacking BAX/BAK also stabilized p53, showed significantly lower levels of gH2AX phosphorylation but no signs of PARP1 cleavage or cell death ( Figure 1B ). This suggests that CHK1i treatment causes DNA damage, triggering a p53-response that precedes BCL2-regulated mitochondrial cell death involving caspase activation. Remarkably though, Hoxb8-FL cells derived from the bone marrow of p53 -/-mice were still highly susceptible to cell death indicating a minor contribution of p53 target genes to apoptosis upon CHK1 inhibition ( Figure 1A ).
Interestingly, we also noted an altered cell cycle distribution in cells that failed to undergo cell death upon CHK1-inhibition. The majority of BCL2-overexpressing or BAX/BAK-deficient cells accumulated in the G1 fraction with a near complete loss of S-phase cells, indicating cell cycle arrest at the G1/S boundary when CHK1 function was inhibited and cell death blocked at the same time ( Figure 1A ,B). Consistently, BAX/BAK-deficient cells showed a significant induction of p21 mRNA in response to CHK1 inhibition ( Figure 1C ). To corroborate this finding, we also performed population-doubling experiments in the presence or absence of CHK1-inhibitor.
Indeed, cells overexpressing BCL2 or cells lacking BAX/BAK failed to proliferate when treated and showed near-constant cell numbers over time ( Figure 1D ).
Together these findings underscore the importance of CHK1 for hematopoietic progenitor cell proliferation and survival by preventing BAX/BAK-mediated apoptotic cell death. Apoptosis seems initiated in response to DNA-damage upon CHK1-inhibition but does not require p53.
When cell death is blocked, these cells show signs of DNA damage and arrest the cell cycle at the G1/S boundary.
CHK1-inhibition kills primary mouse and human HSPCs via BCL2-regulated apoptosis
To get a first impression how CHK1 inhibition affects primary HSPCs, we isolated CHK1i. Consistently, when we treated total fetal liver (FL) or total bone marrow cell cultures that both contain a substantial number of lineage-committed cycling hematopoietic progenitors with CHK1i, we observed a dose-dependent response, driving a significant portion of cells into apoptosis. Again, cell death was significantly reduced when BCL2 was overexpressed ( Figure   2B ,C). This suggests that actively cycling hematopoietic progenitors are more vulnerable, compared to LSK cells, suggesting that cell cycle rates define susceptibility to CHK1i.
To test whether these observations also hold true for human cells, we purified CD34 + HSPCs from the cord-blood that reportedly express low level CHK1 (47) . Indeed, a significant fraction of CD34 + cells died when treated with increasing doses of CHK1i in the presence of proliferation-inducing cytokines ( Figure S1A ). This cell death was potently blocked by the pancaspase inhibitor QVD pointing towards mitochondrial cell death ( Figure 3A ). In line with our findings in mouse cells, cell death was reduced when BCL2 was introduced into CD34 + cells by viral gene transfer ( Figure 3B ) and led to an enrichment of GFP + cells, marking viral transduction, upon treatment ( Figure 3C , Figure S1B ). Moreover, human CD34 + HSPCs lost their potential to form colonies in methyl-cellulose when CHK1 was inhibited chemically ( Figure   S1C ). In line with our experiments using Hoxb8-FL cells, BCL2 overexpression failed to rescue colony formation upon CHK1i inhibition ( Figure 3D ).
Together, this suggests that BCL2-regulated and caspase-dependent apoptosis is initiated also in CD34 + human HSPCs treated with CHK1-inhibitor expanded ex vivo and that blocking cell death is insufficient to restore their clonal outgrowth, most likely because of cell cycle arrest, or, less likely, induction of non-apoptotic cell death.
CHK1 is essential for establishing hematopoiesis in the fetal liver
Our data indicate that CHK1 might be critical also for the development of a functional hematopoietic system. To explore this genetically, we crossed mice harboring a conditional allele of Chk1 with a CRE-deleter strain specific for the hematopoietic system (48) . Deletion of Regardless, fetal liver cells overexpressing BCL2 were again unable to give rise to colonies in metho-cult assays ( Figure 7D ). This suggests that HSPCs that may survive the loss of CHK1 in the presence of high BCL2 levels fail to expand but undergo cell cycle arrest. Consistently, western analysis performed on E14.5 fetal liver cells confirmed that expression levels of CHK1
were drastically reduced in knockout embryos, as was the expression of Cyclin D, suggesting that the residual FL cells present were not cycling. Notably, BCL2 overexpression did not affect the loss of Cyclin D, confirming that when cell death is blocked, these cells fail to thrive.
Taken together, our findings suggest that HSPCs depend on CHK1 to prevent the accumulation of DNA damage during cell cycle progression during fetal liver colonization and that in its absence these cells undergo apoptosis. Yet, when intrinsic apoptosis is impaired, cell cycle arrest prevents HSPC expansion as a second barrier to prevent subsequent mutational spread.
DISCUSSION
HSC are responsible for the supply of blood cells throughout our lifetime. Therefore, it is essential to control their stemness in response to proliferative cues to avoid stem cell exhaustion driving hematopoietic failure and to prevent accumulation of DNA damage or mutations that might contribute to malignant disease with age. CHK1 is a key-regulator of DNAreplication fidelity and the G2/M transition upon DNA damage, critical in early embryogenesis and meanwhile a recognized target in cancer therapy (23, 50) . Yet, the impact of CHK1 loss or inhibition on normal hematopoiesis remains largely unknown.
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